ClinicalTrials.gg

Program

EZH1/2 Inhibitor HH2853

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Lymphoma, Follicular, led by Haihe Biopharma.

Furthest: phase 2, since May 6, 20202 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haihe Biopharma22 open or runningphase 2since May 6, 2020May 6, 2020Dec 31, 2027phase 2 · NCT04390737

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2020First study: phase 2 study in Lymphoma, FollicularFirst studyNCT04390737 · 254 planned · United States, China
  2. Mar 20, 2025Phase 2 study in RecurrenceNCT06909877 · 100 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT04390737

TargetBeta

EZH1 →EZH2 →read by rule
“An orally bioavailable inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tulmimetostatNovartisphase 23
valemetostatruleDaiichi Sankyophase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06909877Recurrence · China2RecruitingOct 31, 2025100
NCT04390737Lymphoma, Follicular · United States, China2RecruitingDec 31, 2027254

How it is read

Names in the registry

  • “HH2853 Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.